A verification study to investigate the drug interaction via CYP3A between oral Midazolam administration and miltiple Anchusan dose in Janaese male subjects

INTERVENTION: Midazolam single oral administration Midazolam single oral administration after 6 days Anchu‐san (7.5g/day) dose CONDITION: Japanese healthy male PRIMARY OUTCOME: The pharmacokinetic parameters of midazolam in serum (AUC 0‐10, Cmax, t1/2, tmax). SECONDARY OUTCOME: The sedative action after midazolam oral administration: VAS; Safety assessment (pulse oximeter, vital measurement, adverse event) INCLUSION CRITERIA: 1) Age: 20 ‐ 45 years old at the time of informed consent 2)Sex: male 3) Subjects are competent to consent, keep the rules of the study and are able to report self condition. 4) Subjects who are judged eligible by the investigator in several series of medical check conducted prior to study.